OPTH ▲ +2.0% - Optimi Health Corp.
$OPTH - Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Optimi Health rose 2.0% after announcing it will initiate a Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder. The advancement to Phase 2 represents a significant milestone in the company's pipeline development and suggests regulatory clearance to proceed with a larger patient study.
10-SEP-2026 08:45 AM ET
Share this post
More filings for $OPTH
OPTH ▲ +2.8% - Optimi Health Corp.Sep 23, 2026OPTH ▲ +0.2% - Optimi Health Corp.Sep 22, 2026OPTH ▲ +4.9% - Optimi Health Corp.Sep 16, 2026OPTH ▲ +0.4% - Optimi Health Corp.Sep 8, 2026OPTH - Optimi Health Corp. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026
View full $OPTH filing history →💬 Comments
Loading comments…
Leave a comment
